HSA
BCRX icon

Hussman Strategic Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Hussman Strategic Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Buy
+210,000
New +$1.9M 0.48% 99
2026
Q1 		– Sell
-252,000
Closed -$1.97M – 279
2025
Q4 		$1.97M Buy
252,000
+42,000
+20% +$304K 0.48% 93
2025
Q3 		$1.59M Hold
210,000
– – 0.35% 132
2025
Q2 		$1.88M Sell
210,000
-105,000
-33% -$978K 0.43% 92
2025
Q1 		$2.36M Buy
+315,000
New +$2.54M 0.57% 58

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Hussman Strategic Advisors's BCRX Position: Q2 2026 in Review

Hussman Strategic Advisors opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 210,000 shares worth $2.1M. The stake represents 0.48% of the portfolio and ranks #99 among its holdings. This is a return to the name: Hussman Strategic Advisors previously reported a position in BCRX as recently as Q4 2025.

Hussman Strategic Advisors first reported a position in BCRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.36M in Q1 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Hussman Strategic Advisors held 210,000 shares of BioCryst Pharmaceuticals worth $2.1M as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Hussman Strategic Advisors position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.48% of Hussman Strategic Advisors's portfolio in Q2 2026, its #99 holding.
  • Hussman Strategic Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Hussman Strategic Advisors's BioCryst Pharmaceuticals position peaked at $2.36M in Q1 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.